News | February 08, 2021
Zydus completes enrolment for two Phase Ill trials of Desidustat
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
The company has concluded our acquisition of Richcore Lifesciences on 20th Jan 2021.
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business
This vaccination programme is based on the principles of priority groups to be vaccinated and health care workers both in the government and private sectors including ICDS workers will receive the vaccine during this phase.
Subscribe To Our Newsletter & Stay Updated
